You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Moodys
Johnson and Johnson
Colorcon
McKesson

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Patent: 6,451,534

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,451,534
Title: KVLQT1--a long QT syndrome gene
Abstract:The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
Inventor(s): Keating; Mark T. (Salt Lake City, UT), Sanguinetti; Michael C. (Salt Lake City, UT), Curran; Mark E. (Encinitas, CA), Landes; Gregory M. (Northboro, MA), Connors; Timothy D. (Hopkinton, MA), Burn; Timothy C. (Hockessin, DE), Splawski; Igor (Salt Lake City, UT)
Assignee: University of Utah Research Foundation (Salt Lake City, UT) Genzyme Corporation (Framingham, MA)
Application Number:09/597,732
Patent Claims:see list of patent claims

Details for Patent 6,451,534

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial University of Utah Research Foundation (Salt Lake City, UT) Genzyme Corporation (Framingham, MA) 2015-12-22 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial University of Utah Research Foundation (Salt Lake City, UT) Genzyme Corporation (Framingham, MA) 2015-12-22 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial University of Utah Research Foundation (Salt Lake City, UT) Genzyme Corporation (Framingham, MA) 2015-12-22 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Medtronic
Harvard Business School
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.